Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.

@article{BeketiOrekovi1995DecreasedMR,
  title={Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.},
  author={Lidija Beketi{\'c}-Ore{\vs}kovi{\'c} and George E. Dur{\'a}n and Kevin G Chen and Charles Dumontet and Branimir Sikic},
  journal={Journal of the National Cancer Institute},
  year={1995},
  volume={87 21},
  pages={
          1593-602
        }
}
BACKGROUND Various mechanisms can contribute to cellular resistance to doxorubicin. These include expression of the multidrug transporter P-glycoprotein (product of the mdr1 gene [also known as PGY1], Mrp (multidrug resistance-associated protein), the p110 major vault protein, altered glutathione metabolism, and altered levels or activity of topoisomerase II (Topo II). We reported recently that single-step treatment of human MES-SA sarcoma cells with 40 nM doxorubicin resulted in selection of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 41 extracted citations

Similar Papers

Loading similar papers…